# A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)

> **NCT02497001** · PHASE3 · COMPLETED · sponsor: **Pearl Therapeutics, Inc.** · enrollment: 1902 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** BGF MDI 320/14.4/9.6 μg
- **DRUG:** GFF MDI (PT003) 14.4/9.6 μg
- **DRUG:** BFF MDI (PT009) 320/9.6 μg
- **DRUG:** Symbicort® Turbuhaler® (TBH) Inhalation Powder

## Key facts

- **NCT ID:** NCT02497001
- **Lead sponsor:** Pearl Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-10
- **Primary completion:** 2018-01-05
- **Final completion:** 2018-01-05
- **Target enrollment:** 1902 (ACTUAL)
- **Last updated:** 2020-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02497001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02497001, "A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02497001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*